Liraglutide

Therapeutic Group

Blood Glucose Lowering Drugs, Excluding Insulin

Indication Dosage

Type 2 Diabetes Mellitus In Combination With Metformin Or A Sulfonylurea, Or Both, Or In Combination With Basal Insulin Or Both Metformin And Pioglitazone When Dual Therapy With These Drugs Fails To Achieve Adequate Glycaemic Control: 

By Sc Inj: 

  • Adult: Initially 0.6 Mg Once Daily For At Least 1 Week, Then Increased To 1.2 Mg Once Daily For At Least 1 Week, Then Increased If Necessary Up To 1.8 Mg Once Daily

Content

  • Inj: Per ml: Liraglutide 6mg 3 ml Pre-Filled Pen

Pregnancy

Contraindicated In Pregnancy.

Stability

  • Glucagon-like Peptide-1 Receptor Agonists

Contra Indications

  • Diabetic Gastroparesis, Ketoacidosis, Inflammatory Bowel Disease, Moderate To Severe Congestive Heart Failure, Hepatic Impairment, Severe Renal Impairment.

Precautions

  • Diabetic Gastroparesis, Ketoacidosis, Inflammatory Bowel Disease, Moderate To Severe Congestive Heart Failure, Hepatic Impairment, Severe Renal Impairment.

Lactation

  • Contraindicated or Not Recommended.

Side Effects

  • Abdominal Pain And Distension
  • Headache
  • Hypoglycaemia
  • Injection Site Reactions
  • Bronchitis
  • Constipation
  • Decreased Appetite
  • Nausea
  • Diarrhoea
  • Dizziness
  • Dyspepsia
  • Flatulence
  • Gastritis
  • Gi Disturbances
  • Gord
  • Malaise
  • Nasopharyngitis
  • Tachycardia
  • Vomiting
  • Goiter.
  • Rare: Acute Renal Failure
  • Increased Blood Calcitonin
  • Thyroid Neoplasm
  • Acute Pancreatitis (discontinue)

Available Brands